Combinatorial  ||| S:0 E:14 ||| JJ
synthesis  ||| S:14 E:24 ||| NN
and  ||| S:24 E:28 ||| CC
in  ||| S:28 E:31 ||| IN
vitro  ||| S:31 E:37 ||| JJ
evaluation  ||| S:37 E:48 ||| NN
of  ||| S:48 E:51 ||| IN
a  ||| S:51 E:53 ||| DT
biaryl  ||| S:53 E:60 ||| JJ
hydroxyketone  ||| S:60 E:74 ||| JJ
library  ||| S:74 E:82 ||| NN
as  ||| S:82 E:85 ||| IN
antivirulence  ||| S:85 E:99 ||| JJ
agents  ||| S:99 E:106 ||| NNS
against  ||| S:106 E:114 ||| IN
MRSA  ||| S:114 E:119 ||| NNP
Antibiotic  ||| S:119 E:130 ||| NNP
resistance  ||| S:130 E:141 ||| NN
coupled  ||| S:141 E:149 ||| VBN
with  ||| S:149 E:154 ||| IN
decreased  ||| S:154 E:164 ||| JJ
development  ||| S:164 E:176 ||| NN
of  ||| S:176 E:179 ||| IN
new  ||| S:179 E:183 ||| JJ
antibiotics  ||| S:183 E:195 ||| NNS
necessitates  ||| S:195 E:208 ||| VBP
the  ||| S:208 E:212 ||| DT
search  ||| S:212 E:219 ||| NN
for  ||| S:219 E:223 ||| IN
novel  ||| S:223 E:229 ||| NN
antibacterial  ||| S:229 E:243 ||| NN
agents ||| S:243 E:249 ||| NNS
.  ||| S:249 E:251 ||| .
Antivirulence  ||| S:251 E:265 ||| JJ
agents  ||| S:265 E:272 ||| NNS
offer  ||| S:272 E:278 ||| VBP
an  ||| S:278 E:281 ||| DT
alternative  ||| S:281 E:293 ||| NN
to  ||| S:293 E:296 ||| TO
conventional  ||| S:296 E:309 ||| JJ
antibiotics ||| S:309 E:320 ||| NN
.  ||| S:320 E:322 ||| .
In  ||| S:322 E:325 ||| IN
this  ||| S:325 E:330 ||| DT
work ||| S:330 E:334 ||| NN
,  ||| S:334 E:336 ||| ,
we  ||| S:336 E:339 ||| PRP
report  ||| S:339 E:346 ||| VBP
on  ||| S:346 E:349 ||| IN
a  ||| S:349 E:351 ||| DT
family  ||| S:351 E:358 ||| NN
of  ||| S:358 E:361 ||| IN
small-molecule  ||| S:361 E:376 ||| JJ
antivirulence  ||| S:376 E:390 ||| JJ
agents  ||| S:390 E:397 ||| NNS
against  ||| S:397 E:405 ||| IN
methicillin-resistant  ||| S:405 E:427 ||| NNP
Staphylococcus  ||| S:427 E:442 ||| NNP
aureus  ||| S:442 E:449 ||| NNS
( ||| S:449 E:450 ||| -LRB-
MRSA ||| S:450 E:454 ||| NNP
) ||| S:454 E:455 ||| -RRB-
,  ||| S:455 E:457 ||| ,
the  ||| S:457 E:461 ||| DT
most  ||| S:461 E:466 ||| RBS
widespread  ||| S:466 E:477 ||| JJ
bacterial  ||| S:477 E:487 ||| JJ
pathogen ||| S:487 E:495 ||| NN
.  ||| S:495 E:497 ||| .
Structure-activity  ||| S:497 E:516 ||| JJ
relationship  ||| S:516 E:529 ||| NN
studies  ||| S:529 E:537 ||| NNS
led  ||| S:537 E:541 ||| VBN
to  ||| S:541 E:544 ||| TO
the  ||| S:544 E:548 ||| DT
development  ||| S:548 E:560 ||| NN
of  ||| S:560 E:563 ||| IN
a  ||| S:563 E:565 ||| DT
concise  ||| S:565 E:573 ||| JJ
synthesis  ||| S:573 E:583 ||| NN
of  ||| S:583 E:586 ||| IN
a  ||| S:586 E:588 ||| DT
148-member  ||| S:588 E:599 ||| JJ
biarylhydroxyketone  ||| S:599 E:619 ||| JJ
library ||| S:619 E:626 ||| NN
.  ||| S:626 E:628 ||| .
An  ||| S:628 E:631 ||| DT
acylation  ||| S:631 E:641 ||| JJ
bond-forming  ||| S:641 E:654 ||| JJ
process  ||| S:654 E:662 ||| NN
afforded  ||| S:662 E:671 ||| VBN
resorcinols  ||| S:671 E:683 ||| NNS
( ||| S:683 E:684 ||| -LRB-
1 ||| S:684 E:685 ||| LS
)  ||| S:685 E:687 ||| -RRB-
and  ||| S:687 E:691 ||| CC
aryloxy  ||| S:691 E:699 ||| JJ
acetonitriles  ||| S:699 E:713 ||| NNS
( ||| S:713 E:714 ||| -LRB-
2 ||| S:714 E:715 ||| LS
)  ||| S:715 E:717 ||| -RRB-
as  ||| S:717 E:720 ||| IN
synthons ||| S:720 E:728 ||| NN
.  ||| S:728 E:730 ||| .
A  ||| S:730 E:732 ||| DT
Lewis-acid-activated  ||| S:732 E:753 ||| JJ
Friedel-Crafts ||| S:753 E:767 ||| NN
'  ||| S:767 E:769 ||| POS
acylation  ||| S:769 E:779 ||| JJ
step  ||| S:779 E:784 ||| NN
involving  ||| S:784 E:794 ||| VBG
a  ||| S:794 E:796 ||| DT
nitrile  ||| S:796 E:804 ||| JJ
functionality  ||| S:804 E:818 ||| NN
of  ||| S:818 E:821 ||| IN
2  ||| S:821 E:823 ||| CD
by  ||| S:823 E:826 ||| IN
ZnCl2 ||| S:826 E:831 ||| NNP
,  ||| S:831 E:833 ||| ,
followed  ||| S:833 E:842 ||| VBN
by  ||| S:842 E:845 ||| IN
nucleophilic  ||| S:845 E:858 ||| JJ
attack  ||| S:858 E:865 ||| NN
by  ||| S:865 E:868 ||| IN
1  ||| S:868 E:870 ||| CD
was  ||| S:870 E:874 ||| VBD
executed  ||| S:874 E:883 ||| VBN
to  ||| S:883 E:886 ||| TO
obtain  ||| S:886 E:893 ||| VB
biaryl  ||| S:893 E:900 ||| JJ
hydroxyketones  ||| S:900 E:915 ||| NN
in  ||| S:915 E:918 ||| IN
excellent  ||| S:918 E:928 ||| JJ
yields ||| S:928 E:934 ||| NNS
.  ||| S:934 E:936 ||| .
A  ||| S:936 E:938 ||| DT
large  ||| S:938 E:944 ||| JJ
number  ||| S:944 E:951 ||| NN
of  ||| S:951 E:954 ||| IN
products  ||| S:954 E:963 ||| NNS
crystallized ||| S:963 E:975 ||| VBD
.  ||| S:975 E:977 ||| .
This  ||| S:977 E:982 ||| DT
strategy  ||| S:982 E:991 ||| NN
affords  ||| S:991 E:999 ||| VBD
a  ||| S:999 E:1001 ||| DT
range  ||| S:1001 E:1007 ||| NN
of  ||| S:1007 E:1010 ||| IN
biarylhydroxyketones  ||| S:1010 E:1031 ||| NN
in  ||| S:1031 E:1034 ||| IN
a  ||| S:1034 E:1036 ||| DT
single  ||| S:1036 E:1043 ||| JJ
step ||| S:1043 E:1047 ||| NN
.  ||| S:1047 E:1049 ||| .
This  ||| S:1049 E:1054 ||| DT
is  ||| S:1054 E:1057 ||| VBZ
the  ||| S:1057 E:1061 ||| DT
first  ||| S:1061 E:1067 ||| JJ
collective  ||| S:1067 E:1078 ||| JJ
synthetic  ||| S:1078 E:1088 ||| JJ
study  ||| S:1088 E:1094 ||| NN
documenting  ||| S:1094 E:1106 ||| VBG
access  ||| S:1106 E:1113 ||| NN
to  ||| S:1113 E:1116 ||| TO
this  ||| S:1116 E:1121 ||| DT
class  ||| S:1121 E:1127 ||| NN
of  ||| S:1127 E:1130 ||| IN
compounds  ||| S:1130 E:1140 ||| NN
through  ||| S:1140 E:1148 ||| IN
a  ||| S:1148 E:1150 ||| DT
single  ||| S:1150 E:1157 ||| JJ
synthetic  ||| S:1157 E:1167 ||| JJ
operation ||| S:1167 E:1176 ||| NN
.  ||| S:1176 E:1178 ||| .
In  ||| S:1178 E:1181 ||| IN
vitro  ||| S:1181 E:1187 ||| JJ
efficacy  ||| S:1187 E:1196 ||| NN
of  ||| S:1196 E:1199 ||| IN
compounds  ||| S:1199 E:1209 ||| NN
in  ||| S:1209 E:1212 ||| IN
this  ||| S:1212 E:1217 ||| DT
library  ||| S:1217 E:1225 ||| NN
was  ||| S:1225 E:1229 ||| VBD
evaluated  ||| S:1229 E:1239 ||| VBN
by  ||| S:1239 E:1242 ||| IN
a  ||| S:1242 E:1244 ||| DT
rabbit  ||| S:1244 E:1251 ||| FW
erythrocyte  ||| S:1251 E:1263 ||| FW
hemolysis  ||| S:1263 E:1273 ||| FW
assay ||| S:1273 E:1278 ||| FW
.  ||| S:1278 E:1280 ||| .
The  ||| S:1280 E:1284 ||| DT
most  ||| S:1284 E:1289 ||| RBS
efficacious  ||| S:1289 E:1301 ||| JJ
compound ||| S:1301 E:1309 ||| NN
,  ||| S:1309 E:1311 ||| ,
4f-12 ||| S:1311 E:1316 ||| NNP
,  ||| S:1316 E:1318 ||| ,
inhibits  ||| S:1318 E:1327 ||| JJ
hemolysis  ||| S:1327 E:1337 ||| NN
by  ||| S:1337 E:1340 ||| IN
98.1  ||| S:1340 E:1345 ||| CD
Â±  ||| S:1345 E:1347 ||| CD
0.1 ||| S:1347 E:1350 ||| CD
%  ||| S:1350 E:1352 ||| NN
compared  ||| S:1352 E:1361 ||| VBN
to  ||| S:1361 E:1364 ||| TO
control  ||| S:1364 E:1372 ||| VB
in  ||| S:1372 E:1375 ||| IN
the  ||| S:1375 E:1379 ||| DT
absence  ||| S:1379 E:1387 ||| NN
of  ||| S:1387 E:1390 ||| IN
the  ||| S:1390 E:1394 ||| DT
compound ||| S:1394 E:1402 ||| NN
.  ||| S:1402 E:1404 ||| .
